Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware.[2] The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.[3]
Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.
History
Incyte Corporation was founded by Roy A. Whitfield on April 8, 1991, in Palo Alto, California, as a genomics company. It became a public company in 1993.[4][5] Subsequently, scientists and chemists were recruited from DuPont to work for Incyte.[4][5] Incyte moved its headquarters to Delaware, and acquired Maxia Pharmaceuticals in 2003.[6][7][8]
In November 2013, Incyte announced its relocation to new headquarters in Wilmington, Delaware, completing the move by the end of 2014.[9][10][11] Hervé Hoppenot became CEO in January 2014.[10]
In 2017, the company became part of the S&P 500 Index, which tracks the 500 most widely held U.S. stocks.[12]
In 2015, Incyte established its European headquarters in Geneva, Switzerland, and later moved this headquarters in 2021.[13][14][15] The company expanded its Delaware headquarters, including the addition of a research and development facility, in 2022.[6] Incyte acquired Villaris Therapeutics in 2022, and Escient Pharmaceuticals in 2024.[16][17]
For 2025, the company reported $5.141 billion in revenue, $6.957 billion in assets and $1.286 billion in net income.[18][19] Incyte is publicly traded on the NASDAQ under the symbol INCY.[5] Incyte now operates out of North America, Asia, and Europe.[20] Bill Meury became CEO in 2025.[21] Meury replaced Hoppenot, who retired after 11 years in the position.[10][21]
Pharmaceuticals
Incyte Corporation currently has seven marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix), Opzelura (Ruxolitinib), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib).[22] [23] In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is marketed under the brand name Tabrecta.[24]
As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.[25][26] It gained EU approval in February 2017.[27] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.[28][29] In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant.[30][31]
As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).[32][33]
Acquisition history
Incyte has made a total of 3 acquisitions.
- Maxia Pharmaceuticals (2003): An early acquisition in Incyte's history, the company purchased Maxia in 2003 for $42 million. [34]
- Villaris Therapeutics (2022): This acquisition was valued at approximately $1.4 billion and included an upfront payment along with milestones. It added new assets to Incyte's portfolio for treating vitiligo and other autoimmune conditions. [35]
- Escient Pharmaceuticals (2024): In May 2024, Incyte acquired this San Diego-based, clinical-stage company for $750 million. The acquisition provided Incyte with two oral drug candidates for inflammatory diseases, EP262 and EP547.[36]
References
- ↑ "Incyte Corp. 2024 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 10, 2025.
- ↑ "INCY". www.nasdaq.com. Retrieved 2021-07-26.
- ↑ "Headquarters - Pharmaceutical Research & Development | Incyte". www.incyte.com. Retrieved 2021-07-27.
- 1 2 Milford, Maureen (November 21, 2014). "Incyte takes over reimagined Wanamaker building". Delaware Online. Retrieved December 12, 2025.
- 1 2 3 "Incyte". Forbes Magazine. 2025. Retrieved December 17, 2025.
- 1 2 Owens, Jacob (April 4, 2022). "Incyte opens new R&D lab in Wilmington". Delaware Business Times. Retrieved December 12, 2025.
- ↑ Baker, Karl (August 5, 2020). "Incyte progresses on COVID-19 treatment. Other big Delaware companies slog through tough economy". Delaware Online. Retrieved December 12, 2025.
- ↑ UNITED STATES SECURITIES AND EXCHANGE COMMISSION (2002). "QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934". SECURITIES AND EXCHANGE COMMISSION. Retrieved December 17, 2025.
- ↑ Malcolm, Wade (November 17, 2013). "Incyte to lease former Wanamaker building near Wilmington". Delaware Online. Retrieved December 12, 2025.
- 1 2 3 Anne Natoli, Cori (January 16, 2014). "Rising Incyte Corp. welcomes new CEO". Delaware Online. Retrieved December 12, 2025.
- ↑ Goss, Scott (March 3, 2015). "Incyte wins Delaware Bio company of the year honor, again". Delaware Online. Retrieved December 12, 2025.
- ↑ Mordock, Jeff (February 28, 2017). "Incyte joins prestigious Standard & Poor's 500 index". Delaware Online. Retrieved December 12, 2025.
- ↑ "Incyte to establish European headquarters in Geneva". 15 July 2020. Retrieved 12 September 2021.
New facility to serve as European base for Incyte's drug development operations, and provides efficient access to key clinical trial experts and institutions.
- ↑ "Prof. Jocelyne Bloch and Prof. Grégoire Courtine receive the BioAlps Academia Award, and Incyte the BioAlps Industry Award". Bio Alps. November 25, 2022. Retrieved May 4, 2026.
- ↑ Wilson, Xerxes (July 31, 2015). "Incyte considering 400 job expansion near Wilmington". Delaware Online. Retrieved May 4, 2026.
- ↑ George, John (October 3, 2022). "Incyte to acquire North Carolina drug developer in deal valued at up to $1.36 billion". Philadelphia Business Journal. Retrieved December 17, 2025.
- ↑ Tabeling, Katie (June 3, 2024). "Incyte closes $750M deal for Escient Pharmaceuticals". Delaware Business Times. Retrieved December 17, 2025.
- ↑ "Incyte Corp. 2025 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 10, 2026.
- ↑ Incyte (February 10, 2026). "Incyte Reports Fourth Quarter and Full Year 2025 Financial Results". Incyte. Archived from the original on March 31, 2026. Retrieved March 31, 2026.
- ↑ Tabeling, Katie (October 23, 2024). "Incyte celebrated at du Pont Freedom Award reception". Delaware Business Times. Archived from the original on May 22, 2025. Retrieved December 17, 2025.
- 1 2 Tabeling, Katie (June 30, 2025). "Meury named Incyte CEO as Hoppenot departs". Delaware Business Times. Archived from the original on March 31, 2026. Retrieved March 31, 2026.
- ↑ "incy_Current folio_10K". www.sec.gov. Retrieved 2021-07-26.
- ↑ "portfolio.pdf" (PDF). www.incyte.com. Retrieved 2022-12-18.
- ↑ "Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development | Business Wire". www.businesswire.com. 29 April 2013. Retrieved 2015-12-29.
- ↑ "Lilly, Incyte Treatment Shows Positive Results". www.insideindianabusiness.com. 9 Dec 2014. Retrieved 2 Mar 2015.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ "Baricitinib" (PDF). Statement on a nonproprietary name adopted by the USAN council. American Medical Association.
- ↑ Ramsey, L (17 April 2017). "The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling". Business Insider.
- ↑ Grant, Ch (14 April 2017). "Surprise FDA Rejection Will Sting This Biotech". The Wall Street Journal.
- ↑ Research, Center for Drug Evaluation and (2019-02-09). "Drug Trials Snapshots: OLUMIANT". FDA. Archived from the original on September 28, 2019.
- ↑ "Drug Approval Package: Olumiant (baricitinib)". www.accessdata.fda.gov. Retrieved 2021-07-27.
- ↑ Brochez, L; Chevolet, I; Kruse, V (May 2017). "The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy". European Journal of Cancer. 76: 167–182. doi:10.1016/j.ejca.2017.01.011. PMID 28324751.
- ↑ Tracy Staton (Apr 3, 2017). "Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials". FiercePharma.
- ↑ "Incyte Acquires Maxia Pharmaceuticals; Acquisition Expands Drug Discovery & Development Programs | Incyte". February 19, 2003.
{{cite web}}: CS1 maint: url-status (link) - ↑ "Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6) | Incyte". October 3, 2022.
{{cite web}}: CS1 maint: url-status (link) - ↑ "Incyte Completes Acquisition of Escient Pharmaceuticals | Incyte".
{{cite web}}: CS1 maint: url-status (link)
External links
- Business data for Incyte:
